gemfibrozil

Gemfibrozil (CI-719) 是一种PPAR-α激活剂，可作为降脂药。它也是P450非选择性抑制剂，对 CYP2C9、2C19、2C8 和 1A2 的Ki 值分别为 5.8、24、69 和 82 μM。

Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil, is a potent and competitive inhibitor of P450 (CYP) isoform CYP2C8, with an IC50 of 4.07 μM.

Gemfibrozil-d6 is intended for use as an internal standard for the quantification of gemfibrozil by GC- or LC-MS. Gemfibrozil is a peroxisome proliferator-activated reporter α and PPARγ agonist. In vivo, gemfibrozil reduces serum total cholesterol, triglyceride, and LDL levels in a rat model of high-cholesterol diet-induced hyperlipidemia. Gemfibrozil reduces atherosclerotic plaque area, superoxide production, and expression of the genes encoding the NF-κB subunit p65 and chemokine (C-C) motif ligand 2 (CCL2) in ApoE-/- mice. Formulations containing gemfibrozil have been used in the treatment of high cholesterol.

Gemfibrozil (Standard) 是 Gemfibrozil 的标准品，适用于定量分析、质量控制及生化实验等相关研究。Gemfibrozil (CI-719) 是一种PPAR-α激活剂，可作为降脂药。它也是P450非选择性抑制剂，对 CYP2C9、2C19、2C8 和 1A2 的Ki 值分别为 5.8、24、69 和 82 μM。

AH057 is a novel JAK inhibitor, effectively blocking the JAK/STAT pathways by directly inhibiting JAK1/2 kinase activities, and leading to compromised cell proliferation and invasion, increasing apoptosis, arrested cell cycles, and impairing tumor progression in vitro and in vivo

Melinamide 是一种降脂化合物，其药理特性类似 gemfibrozil。Melinamide 主要通过降低甘油三酯丰富的极低密度脂蛋白 (VLDL) 来减少血清脂质升高。在 III 型高脂蛋白血症中，当胆固醇升高源自中密度脂蛋白 (IDL) 时，Melinamide 可降低血清胆固醇水平。